177 related articles for article (PubMed ID: 23635399)
21. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical results obtained with Ki67-labeling and PHH3-mitosis index in glial tumors: a literature analysis.
Elmaci İ; Altinoz MA; Bolukbasi FH; Yapicier O; Sav A
Clin Neuropathol; 2017; 36(6):272-282. PubMed ID: 28853695
[TBL] [Abstract][Full Text] [Related]
23. Mitotic Index Determined by Phosphohistone H3 Immunohistochemistry for Precise Grading in Follicular Lymphoma.
Bedekovics J; Irsai G; Hegyi K; Beke L; Krenács L; Gergely L; Méhes G
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):579-585. PubMed ID: 27997502
[TBL] [Abstract][Full Text] [Related]
24. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.
Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC
Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
26. [Accurate grading of pancreatic neuroendocrine tumors with Ki-67 index in fine-needle aspiration specimens: a comparative cytologic and histologic study].
He SR; Cui D; Gong H; Zhu YP; Chen L; Hu ST; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):393-399. PubMed ID: 28591986
[No Abstract] [Full Text] [Related]
27. Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors.
Alkhasawneh A; Reith JD; Toro TZ; Ayed AO; Lu X; George TJ; Duckworth LV
Am J Clin Pathol; 2015 Mar; 143(3):385-92. PubMed ID: 25696796
[TBL] [Abstract][Full Text] [Related]
28. EPIGENETIC CHANGES - HISTONE 3 PHOSPHORYLATION - EPITHELIAL OVARIAN TUMORS.
Munjishvili V; Barabadze E; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 Sep; (294):128-131. PubMed ID: 31687964
[TBL] [Abstract][Full Text] [Related]
29. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
[TBL] [Abstract][Full Text] [Related]
30. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
Yang Z; Tang LH; Klimstra DS
Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
32. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
33. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
34. The Utility of Phosphohistone H3 in Breast Cancer Grading.
Cui X; Harada S; Shen D; Siegal GP; Wei S
Appl Immunohistochem Mol Morphol; 2015; 23(10):689-95. PubMed ID: 25611243
[TBL] [Abstract][Full Text] [Related]
35. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).
Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM
J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
Kim YJ; Ketter R; Steudel WI; Feiden W
Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
[TBL] [Abstract][Full Text] [Related]
37. Improving mitotic cell counting accuracy and efficiency using phosphohistone-H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading.
Ibrahim A; Toss MS; Makhlouf S; Miligy IM; Minhas F; Rakha EA
Histopathology; 2023 Feb; 82(3):393-406. PubMed ID: 36349500
[TBL] [Abstract][Full Text] [Related]
38. Ki67 index and mitotic count: Correlation and variables affecting the accuracy of the quantification in endocrine/neuroendocrine tumors.
Huang W; Nebiolo C; Esbona K; Hu R; Lloyd R
Ann Diagn Pathol; 2020 Oct; 48():151586. PubMed ID: 32836178
[TBL] [Abstract][Full Text] [Related]
39. Anti-phosphohistone H3 as an independent prognostic factor in human esophageal squamous cell carcinoma.
Nakashima S; Shiozaki A; Ichikawa D; Komatsu S; Konishi H; Iitaka D; Kubota T; Fujiwara H; Okamoto K; Kishimoto M; Otsuji E
Anticancer Res; 2013 Feb; 33(2):461-7. PubMed ID: 23393337
[TBL] [Abstract][Full Text] [Related]
40. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.
Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN
Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
